A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors

Trial Profile

A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Futuximab/modotuximab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck KGaA
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016.
    • 07 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top